Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 5/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722214 | 0.84 | GPR119 (0.38) | GPR119GBA1SPRMAPTCKS1B | |
| SCHEMBL21734104 | 0.82 | GBA1 (0.44) | GPR119SMN1; SMN2GBA1SPREHMT2 | |
| SCHEMBL21722183 | 0.81 | GBA1 (0.44) | GPR119GBA1SPREHMT2MAPT | |
| SCHEMBL22720305 | 0.81 | GBA1 (0.45) | GBA1SPREHMT2MAPTCKS1B | |
| SCHEMBL25244232 | 0.79 | GPR119 (0.40) | GPR119GBA1CKS1BSKP1SKP2 | |
| SCHEMBL30454942 | 0.79 | GPR119 (0.40) | GPR119GBA1CKS1BSKP1SKP2 | |
| SCHEMBL19617028 | 0.77 | GPR119 (0.45) | GPR119 | |
| SCHEMBL30422250 | 0.76 | MTOR (0.44) | GPR119GBA1 | |
| SCHEMBL29245996 | 0.76 | P2RX3 (0.43) | GPR119GBA1MAPTCKS1BSKP1 | |
| SCHEMBL22360879 | 0.74 | MTOR (0.45) | GPR119GBA1MAPTCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | GPR119 1771/4885SMN1; SMN2 3687/4885L3MBTL1 4098/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | GPR119 1771/4885SMN1; SMN2 3687/4885L3MBTL1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.